Skip to main content
SPT logo

SPT — Investor Relations & Filings

Ticker · 1789 ISIN · TW0001789006 TW Manufacturing
Open in API
Filings indexed 2,231 across all filing types
Latest filing 2025-12-16 Governance Information
Country TW Taiwan
Listing TW 1789

About SPT

https://www.scinopharm.com/tw

ScinoPharm Taiwan, Ltd. is a global provider of high-quality Active Pharmaceutical Ingredients (APIs) and comprehensive Contract Development and Manufacturing Organization (CDMO) services. The company specializes in process research, development, and cGMP production, maintaining a leadership position in oncology APIs. Its portfolio covers therapeutic areas including cancer, hematology, metabolic disorders, and central nervous system diseases. ScinoPharm offers one-stop solutions encompassing peptide synthesis, API process development, and the manufacturing of sterile injectables and complex generics. The company is distinguished by its expertise in high-barrier pharmaceutical technologies and adherence to stringent international regulatory standards, such as the U.S. FDA. Serving both generic and innovative drug sectors, it leverages advanced R&D and integrated manufacturing to support global healthcare markets.

Recent filings

Filing Released Lang Actions
公司治理組織架構
Governance Information Classification · 95% confidence The document is a tabular disclosure of company governance information, including details about board composition, director terms, independent directors, audit committee setup, remuneration committee, legal counsel, and shareholder relations contacts. It references company governance and mentions that related information can be found in the company's annual report. The document length is short (1461 characters) and does not contain financial statements or detailed management discussion. It is a governance-related disclosure rather than a full report or announcement of voting results. Therefore, it fits best under Governance Information (CGR).
2025-12-16 Chinese
114年12月法人說明會簡報 — 178920251211E001.pdf
Investor Presentation Classification · 95% confidence The document is titled 'ScinoPharm Investor Conference 2025 12 11' and contains detailed sections including Company Overview, Business Update, and Financial Performance with consolidated income statement, balance sheet, and cash flow statement for 3Q 2025. It also includes forward-looking statements and a Q&A section. The content is typical of an investor presentation focusing on financials, strategy, and market position rather than a formal regulatory filing or earnings release. The length (11,851 characters) and detailed financial data support this classification. There is no indication that this is a full annual or interim report, audit report, or earnings release. It is clearly a presentation prepared for investors, consistent with the 'Investor Presentation' category.
2025-12-11 Chinese
114年12月法人說明會簡報 — 178920251211M001.pdf
Investor Presentation Classification · 95% confidence The document is a detailed presentation from ScinoPharm Taiwan, Ltd. dated December 11, 2025, containing company overview, business status, financial performance including income statement, balance sheet, and cash flow statement for the first three quarters of 2025, as well as business development and product pipeline information. It includes forward-looking statements, detailed operational and financial data, and a Q&A section. The content is typical of an investor presentation focusing on financials, strategy, and market position rather than a formal annual or quarterly report filing. The length is over 7,000 characters, indicating it is a full presentation rather than a brief announcement. There is no indication that this is an official regulatory filing, audit report, or earnings release. Therefore, the document best fits the category of Investor Presentation (IP).
2025-12-11 Chinese
114年12月法人說明會簡報
Investor Presentation Classification · 95% confidence The document is a listing from a public information observation station showing details about a company's investor conference call or presentation. It includes the company code, name, date and time of the investor meeting, location (online), a summary of the meeting content, links to presentation materials (PDFs), and video links. The content specifically mentions a "法人說明會" which translates to "investor presentation" or "investor conference." The document is short (911 characters) and primarily provides information about the event and links to presentation materials rather than the full transcript or detailed financial report. Therefore, this document is best classified as an Investor Presentation (IP).
2025-12-11 Chinese
114年第3季財務報告書 — 202504_1789_AIC.pdf
Regulatory Filings
2025-12-10 Chinese
114年第3季財務報告書 — 202504_1789_AIA.pdf
Regulatory Filings
2025-12-10 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.